07:21:28 EDT Sun 14 Jun 2026
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 16 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-06-14 05:15U:CLDXNews ReleaseCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
2026-06-14 03:15U:LLYNews ReleaseLilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
2026-06-14 03:15U:LEGNNews ReleaseLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
2026-06-13 22:16U:ELEKNews ReleaseElektros Inc. Ignites New Momentum Across Lithium, EV Innovation, and Critical Minerals as the Global Electrification Era Accelerates
2026-06-13 21:30U:ELEKNews ReleaseElektros Inc. Powers Ahead as Global Demand for Lithium, EV Innovation, and Critical Minerals Creates New Opportunities for Electrification
2026-06-13 21:15U:ELEKNews ReleaseElektros Inc. Accelerates Its Vision for Lithium, EV Innovation, and the Future of Electrification
2026-06-13 21:00U:ELEKNews ReleasePowering the Future of Electrification
2026-06-13 20:00U:ACDVFNews ReleaseAir Canada and the IAMAW Reach Tentative Agreement on New Contract
2026-06-13 18:15U:CYCLNews ReleaseCycclone, Inc. Announces Agreement in Principle for the Acquisition of AI Robotics Company
2026-06-13 16:00U:ASNDNews ReleasePhase 3 Data Show TransCon(TM) PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
2026-06-13 12:45U:GMABNews ReleaseGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2026-06-13 11:15U:LLYNews ReleaseLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
2026-06-13 11:15U:INCYNews ReleaseIncyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
2026-06-13 09:00U:AGIONews ReleaseAgios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
2026-06-13 08:01U:RYTMNews ReleaseRhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
2026-06-13 07:30U:NTLANews ReleaseIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema